Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$120.17 +0.9%	$131.78	$110.04 ▼ $238.00	$17.59B	0.06	1.34 million shs	1.00 million shs
BMRN BioMarin Pharmaceutical	$63.28 +0.5%	$66.24	$52.93 ▼ $94.85	$12.07B	0.3	1.86 million shs	1.23 million shs
HALO Halozyme Therapeutics	$60.82 +0.4%	$60.63	$37.97 ▼ $66.00	$7.51B	1.32	1.43 million shs	1.15 million shs
UTHR United Therapeutics	$300.76 +1.3%	$305.66	$233.31 ▼ $417.82	$13.51B	0.63	446,465 shs	574,876 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+0.88%	+1.08%	-13.15%	-16.79%	-44.24%
BMRN BioMarin Pharmaceutical	+0.48%	+2.89%	-11.42%	-0.28%	-22.95%
HALO Halozyme Therapeutics	+0.41%	+4.48%	-4.73%	+8.94%	+56.87%
UTHR United Therapeutics	+1.25%	+2.71%	-2.02%	-19.31%	+26.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.7034 of 5 stars	4.2	3.0	3.7	2.6	2.5	1.9
BMRN BioMarin Pharmaceutical	4.9209 of 5 stars	4.3	3.0	3.3	3.5	2.5	3.1
HALO Halozyme Therapeutics	4.0106 of 5 stars	1.3	1.0	4.4	2.1	2.5	4.4
UTHR United Therapeutics	4.9068 of 5 stars	3.3	4.0	4.6	3.0	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$201.93	68.03% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$93.14	47.19% Upside
HALO Halozyme Therapeutics	2.60	Moderate Buy	$62.89	3.40% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$390.17	29.73% Upside

Current Analyst Ratings Breakdown

Latest HALO, BIIB, UTHR, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	BIIB Biogen	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$210.00 ➝ $199.00
4/29/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$135.00 ➝ $115.00
4/28/2025	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$118.00
4/28/2025	BIIB Biogen	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/25/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/25/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
4/25/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$395.00 ➝ $314.00
4/23/2025	BIIB Biogen	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$219.00 ➝ $197.00
4/22/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$221.00 ➝ $225.00
4/21/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$55.00 ➝ $58.00
4/21/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$357.00 ➝ $355.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	1.82	$19.73 per share	6.09	$114.71 per share	1.05
BMRN BioMarin Pharmaceutical	$2.85B	4.23	$2.99 per share	21.17	$29.69 per share	2.13
HALO Halozyme Therapeutics	$1.02B	7.40	$4.92 per share	12.35	$2.95 per share	20.62
UTHR United Therapeutics	$2.88B	4.69	$18.09 per share	16.63	$127.35 per share	2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$11.19	10.74	7.28	1.51	16.87%	14.98%	8.76%	5/1/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$167.65M	$2.20	28.76	14.51	0.61	14.96%	9.91%	7.65%	5/1/2025 (Estimated)
HALO Halozyme Therapeutics	$281.59M	$3.43	17.73	9.78	0.42	43.74%	157.78%	25.34%	5/6/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.21	10.94	0.97	40.31%	19.22%	16.15%	4/30/2025 (Estimated)

Latest HALO, BIIB, UTHR, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	N/A	N/A	N/A	$231.21 million	N/A
5/1/2025	Q1 2025	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
5/1/2025	Q1 2025	BMRN BioMarin Pharmaceutical	$0.95	N/A	N/A	N/A	$741.84 million	N/A
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	N/A
2/26/2025	Q4 2024	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/19/2025	Q4 2024	BMRN BioMarin Pharmaceutical	$0.54	$0.72	+$0.18	$0.64	$711.05 million	$747.31 million
2/18/2025	Q4 2024	HALO Halozyme Therapeutics	$1.17	$1.19	+$0.02	$1.06	$285.74 million	$298.01 million
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
BMRN BioMarin Pharmaceutical	0.11	5.33	2.62
HALO Halozyme Therapeutics	4.14	7.80	9.15
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
HALO Halozyme Therapeutics	97.79%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
BMRN BioMarin Pharmaceutical	0.85%
HALO Halozyme Therapeutics	2.40%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BMRN BioMarin Pharmaceutical	3,080	190.80 million	187.06 million	Optionable
HALO Halozyme Therapeutics	390	123.53 million	120.20 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

HALO, BIIB, UTHR, and BMRN Headlines

Recent News About These Companies

United Therapeutics Corporation Reports First Quarter 2025 Financial Results | UTHR Stock News

April 30 at 8:38 AM | gurufocus.com

United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue

April 30 at 8:38 AM | gurufocus.com

United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations

April 30 at 8:38 AM | gurufocus.com

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

April 30 at 8:38 AM | gurufocus.com

United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates

April 30 at 8:35 AM | zacks.com

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

April 30 at 6:30 AM | businesswire.com

Voya Investment Management LLC Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 30 at 5:39 AM | marketbeat.com

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

April 29 at 8:28 AM | msn.com

2,926 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Prosperity Consulting Group LLC

April 29 at 6:43 AM | marketbeat.com

Integrated Wealth Concepts LLC Acquires 1,230 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 29 at 5:40 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stock Position Raised by Price T Rowe Associates Inc. MD

April 29 at 5:15 AM | marketbeat.com

Leerink Partnrs Has Bullish Estimate for UTHR Q1 Earnings

April 29 at 1:18 AM | americanbankingnews.com

Q1 EPS Forecast for United Therapeutics Lifted by Analyst

April 29 at 1:16 AM | marketbeat.com

Nitorum Capital L.P. Has $33.67 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:46 AM | marketbeat.com

Susquehanna Fundamental Investments LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:45 AM | marketbeat.com

Nebula Research & Development LLC Invests $1.62 Million in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:17 AM | marketbeat.com

Dark Forest Capital Management LP Makes New $540,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 5:07 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by TD Waterhouse Canada Inc.

April 28 at 4:45 AM | marketbeat.com

Canada Pension Plan Investment Board Sells 13,000 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 4:18 AM | marketbeat.com

Jump Financial LLC Buys Shares of 1,046 United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 4:10 AM | marketbeat.com

Wells Fargo & Company Reaffirms Equal Weight Rating for United Therapeutics (NASDAQ:UTHR)

April 28 at 2:13 AM | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO, BIIB, UTHR, and BMRN Company Descriptions

Biogen NASDAQ:BIIB

$120.17 +1.05 (+0.88%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$119.33 -0.84 (-0.70%)

As of 08:57 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$63.28 +0.30 (+0.48%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$63.14 -0.13 (-0.21%)

As of 09:04 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Halozyme Therapeutics NASDAQ:HALO

$60.82 +0.25 (+0.41%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$61.22 +0.40 (+0.66%)

As of 09:05 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$300.76 +3.72 (+1.25%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$314.46 +13.70 (+4.56%)

As of 09:03 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time